Treasury Secretary Bessent announces tariff relief on coffee, fruits
Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), sold 12,400 shares of common stock on September 24 and 25, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The micro-cap biotech company, currently valued at $29.07 million, trades above its InvestingPro Fair Value despite analyst targets ranging from $30 to $45.
The sales, executed in two separate transactions, totaled $174175. On September 24, Szot sold 1,500 shares at a weighted average price of $13.9953, for $20993. Prices ranged from $13.99 to $14.02. Following this transaction, Szot still directly owned 29,833 shares. The following day, September 25, Szot sold 10,900 shares at a weighted average price of $14.0534, for $153182. Prices ranged from $13.99 to $14.52. Following this transaction, Szot still directly owned 18,933 shares. The insider selling comes as the company faces rapid cash burn, though it maintains a healthy current ratio of 3.56. Want deeper insights into insider trading patterns and 8 additional key metrics? Check out InvestingPro.
In other recent news, Cadrenal Therapeutics , Inc. has acquired the assets of eXIthera Pharmaceuticals, expanding its portfolio with investigational Factor XIa inhibitors for anticoagulation therapy. This acquisition includes two drug candidates: frunexian, which is ready for Phase 2 trials as an intravenous Factor XIa inhibitor for acute care, and EP-7327, an oral inhibitor for chronic thrombotic conditions. Additionally, Cadrenal Therapeutics announced the resignation of Robert Lisicki from its board of directors. The company clarified that his departure was not due to any disagreements with its operations or policies. Furthermore, Cadrenal Therapeutics has scheduled its 2025 annual meeting of stockholders for September 24, 2025. Shareholders eligible to vote at the meeting will be determined as of July 28, 2025. More information about the meeting will be included in the upcoming proxy statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.